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ABSTRACT
Background: Early detection and appropriate management of chronic kidney disease (CKD) in
primary care are essential to reduce morbidity and mortality. Aim: To assess the quality of care
(QoC) of CKD in primary healthcare in relation to patient and practice characteristics in order to
tailor improvement strategies. Design and setting: Retrospective study using data between 2008
and 2011 from 47 general practices (207 469 patients of whom 162 562 were adults). Method: CKD
management of patients under the care of their general practitioner (GP) was qualified using
indicators derived from the Dutch interdisciplinary CKD guideline for primary care and nephrology
and included (1) monitoring of renal function, albuminuria, blood pressure, and glucose, (2)
monitoring of metabolic parameters, and alongside the guideline: (3) recognition of CKD. The
outcome indicator was (4) achieving blood pressure targets. Multilevel logistic regression analysis
was applied to identify associated patient and practice characteristics. Results: Kidney function or
albuminuria data were available for 59 728 adult patients; 9288 patients had CKD, of whom 8794
were under GP care. Monitoring of disease progression was complete in 42% of CKD patients,
monitoring of metabolic parameters in 2%, and blood pressure target was reached in 43.1%. GPs
documented CKD in 31.4% of CKD patients. High QoC was strongly associated with diabetes, and to
a lesser extent with hypertension and male sex. Conclusion: Room for improvement was found in
all aspects of CKD management. As QoC was higher in patients who received structured diabetes
care, future CKD care may profit from more structured primary care management, e.g. according to
the chronic care model.
KEY POINTS
 Quality of care for chronic kidney disease patients in primary care can be improved.
 In comparison with guideline advice, adequate monitoring of disease progression was observed
in 42%, of metabolic parameters in 2%, correct recognition of impaired renal function in 31%,
and reaching blood pressure targets in 43% of chronic kidney disease patients.
 Quality of care was higher in patients with diabetes.
 Chronic kidney disease management may be improved by developing strategies similar to
diabetes care.
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Introduction
General practitioners (GPs) play a key role in the complex
care of patients with chronic kidney disease (CKD).
The K/DOQI guidelines (USA) and the National Institute
for Health and Clinical Excellence (NICE) CKD guideline
(UK) provide GPs with recommendations on good CKD
management, including monitoring of disease progres-
sion and strictly controlling cardiovascular risk
factors.[1,2] The Dutch interdisciplinary CKD guideline
for primary care and nephrology is similar to these
guidelines, but incorporates age in its recommendations
(Web appendix Table 1).[3]
Studies have shown that high standard CKD man-
agement attenuates and delays adverse outcomes such
as progression to end-stage renal failure and cardio-
vascular events.[4,5] However, literature also notes
deficiencies in the quality of care (QoC).[6,7] The high
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prevalence of comorbidity challenges the GP to
balance guideline advice to the patient’s individual
needs.[8]
Our study aimed to analyse QoC in routine general
practice for all stages of CKD, in relation to patient and
practice characteristics. We hypothesized that our study
would reveal predictors of high QoC.
Material and methods
Recruitment of participants
This retrospective study used baseline patient data of
general practices that participated in a cluster rando-
mized controlled trial on the effect of web consultation
between GP and nephrologist on in-person referrals: the
CONTACT study (Consultation Of Nephrology by
Telenephrology Allows optimal Chronic kidney disease
Treatment in primary care, Netherlands Trial Registration
code 2368). The CONTACT study recruited general
practices during a CKD management course for GPs.
Forty-seven non-academic general practices signed up
for participation. Data between 2008 and 2011 were
analysed from their registered populations’ electronic
medical records (EMRs) (n¼ 207 469). We included all
patients aged 18 years or older who met the CKD
criteria: eGFR560ml/min/1.73m2 or albuminuria.
Patients under secondary renal care were excluded
from analysis.
Classification of patients
The interdisciplinary CKD guideline for primary care and
nephrology provides guidance for the GP in selecting
the best suited health care setting for patients with CKD,
based on eGFR, albuminuria and age. These settings are:
treatment in primary care, consultation with a neph-
rologist without referral, and referral to secondary care.
The guideline provides specific monitoring criteria for
each group. We applied this classification to our cohort,
resulting in a primary care, a consultation, and a
referral group (Table 1). For the primary care group
this implied monitoring of disease progression, while the
consultation and the referral groups additionally
required monitoring of metabolic parameters (Web
appendix Table 1). We used laboratory-reported MDRD
calculated eGFR values and in congruence with the
guideline we defined microalbuminuria as a urinary
albumin to creatinine ratio (ACR) of 2.5–25mg/mmol in
men and 3.5–35mg/mmol in women. Higher ratios
reflected macroalbuminuria. If an ACR was unavailable,
we used urine albumin concentration with cut-off
values420–200mg/l for microalbuminuria and4200
mg/l for macroalbuminuria. Patient age was set on the
latest eGFR date.
Process and outcome indicators
We derived indicators (Table 2) from the interdisciplinary
CKD guideline for primary care and nephrology.[3]
Included process indicators were: (1) monitoring of
disease progression (assessment of eGFR or serum
creatinine, albuminuria, glucose, and blood pressure);
(2) monitoring of metabolic parameters (assessment of
haemoglobin, calcium, phosphate, parathyroid hormone
(PTH), serum albumin, and potassium), and alongside
the guideline: (3) recognition of CKD in patients with an
eGFR560ml/min/1.73m2 (separate entity on the EMR
episode list with International Classification of Primary
Care (ICPC) code U99.1 for renal impairment). The
outcome indicator was (4) achievement of blood pres-
sure targets, for which the mean of the two latest
measurements had to be5140/90mmHg. Additionally,
we analysed blood pressures 5130/80mmHg to allow
comparison with existing literature.
Patient and practice characteristics
We extracted patient demographic and clinical data
concerning comorbidities and medication from the EMRs
(Table 3). Patient age was categorized in ranges 18–45,
45–60, 60–75, and over 75 years. Comorbidities were
defined by ICPC codes as a history of diabetes (T90),
hypertension (K86,K87), and cardiovascular disease (K74-
K77,K89,K90,K92).[9] We selected drug prescriptions
issued during 2010 for medication shown in Table 3
using Anatomical Therapeutic Chemical (ATC) codes.[10]
Practice characteristics included type (solo, duo, or
group practice), vocational training, location (urban or
Table 1. Classification of adult patients with available renal
function using the interdisciplinary CKD guideline for primary
care and nephrology.
Albuminuria
Not known Normal Microalbuminuria Macroalbuminuria
Patients 65 years (n¼ 19 887)
eGFR 60 7.696 5.467 893 74
eGFR 45–60 2.085 1.632 411 52
eGFR 30–45 620 442 195 46
eGFR530 179 44 33 18
Patients565 years (n¼ 39 841)
eGFR 60 28.927 8.350 693 59
eGFR 45–60 869 620 70 16
eGFR 30–45 102 55 22 7
eGFR530 33 4 6 8
Classification of patients based on renal function, albuminuria and age.
‘‘Primary care group’’ n = 5714: treatment in primary care. ‘‘Consultation
group’’ n = 2816: consultation with a nephrologist without referral.
‘‘Referral group’’ n = 758: referral to secondary care. eGFR in ml/min/
1.73m2
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rural based on the Statistics Netherlands’ Key figures
postcode areas database of 2004), and General Practice
Information System (Web appendix Table 2).
Data analysis
CKD stage prevalence was calculated using the regis-
tered population aged 18 years and over as denomin-
ator. We used descriptive statistics to assess adherence
to process and outcome indicators and to evaluate GPs’
recognition of CKD. The guideline advises annual moni-
toring, but in routine general practice the monitoring
could take place outside this 12-month timeframe. We
took this into account and extended the period to 15
months prior to data extraction on 1 March 2011.
Because of the hierarchical structure of our data
(patients nested within practices) the analyses were
based on the multilevel logistic regression model (PROC
GLIMMIX in SAS). To identify patient and practice
characteristics associated with high-quality care, we
performed a model with a random intercept and all
other variables were fixed. The type of General Practice
Information System was considered a confounder, since
it could affect the quality of data recording. We started
with a full model including all independent variables and
excluded statistically non-significant variables one by
one in a backward procedure. We considered a p-value
50.05 as statistically significant. Descriptive analysis was
conducted using SPSS version 20.0 (IBM PASW statis-
tics 20, IBM, Armonk, NY, USA) and multilevel logistic
regression analysis was conducted using SAS V9.2 (SAS
Institute, Cary, NC, USA).
Results
Practice population
The 47 practices served a population of 207 469 people
of whom 162 562 were aged 18 or older. Data on renal
function (n¼ 59 728) or albuminuria (n¼ 19 217) were
present for 59 728 adult patients (31%). More data were
Table 3. Patient characteristics based on data from 2008 to 2011 for patients under GP care.
Patient characteristic Groups
Overall (n¼ 8794) Primary care (n¼ 5710) Consultation (n¼ 2780) Referral (n¼ 304)
Demographics (SD):
Age in years 71.4 (11.9) 73.6 (10.2) 66.7 (13.3) 72.3 (14.0)
Male sex 40.0% 42.7% 33.6% 47.0%
Comorbidity:
Diabetes 32.9% 36.0% 24.5% 52.6%
Hypertension 56.2% 57.8% 53.5% 52.0%
Cardiovascular disease 35.6% 36.1% 32.4% 53.6%
Laboratory (SD), n:
Creatinine, mmol/l 103.9(25.9) [n¼ 8792] 95.6 (18.5) [n¼ 5709] 117.4 (23.7) [n¼ 2779] 136.7 (61.6) [n¼ 304]
eGFR, ml/min/1.73m2 52.6 (8.1) [n¼ 8794] 55.4 (4.9) [n¼ 5710] 47.7 (9.0) [n¼ 2780] 43.0 (15.1) [n¼ 304]
Fasting glucose, mmol/l 6.5 (1.8) [n¼ 6938] 6.6 (1.9) [n¼ 4689] 6.2 (1.6) [n¼ 1998] 7.0 (2.3) [n¼ 251]
Haemoglobin, g/dl 13.50 (1.56) [n¼ 2085] 12.78 (1.96) [n¼ 227]
Calcium, mmol/l 2.33 (0.12) [n¼ 445] 2.32 (0.14) [n¼ 72]
Phosphate, mmol/l 1.03 (0.18) [n¼ 341] 1.15 (0.20) [n¼ 46]
PTH, pmol/l 7.51 (4.70) [n¼ 138] 7.34 (5.42) [n¼ 13]
Albumin, g/l 38.8 (4.4) [n¼ 271] 38.6(4.6) [n¼ 57]
Potassium, mmol/l 4.3 (0.45) [n¼ 2238] 4.4 (0.56) [n¼ 270]
Urine (first and third quartile), n
Albumin urine, mg/l 15.0 (3.4–51.0) [n¼ 2928] 20.0 (5.0-53.0) [n¼ 2049] 6.0 (2.9-18.0) [n¼ 721] 210.6 (84.3–480.2) [n¼ 158]
Albumin/creatinine ratio 2.5 (0.9-6.1) [n¼ 5022] 3.2 (0.9-6.4) [n¼ 3557] 0.9 (0.8-2.3) [n¼ 1254] 37.7 (14.8-58.2) [n¼ 211]
Physical examination (SD), n
Diastolic blood pressure, mm Hg 78.8 (9.7) [n¼ 7291] 78.6 (9.5) [n¼ 4889] 79.1 (9.9) [n¼ 2147] 78.6 (11.3) [n¼ 255]
Systolic blood pressure, mm Hg 142.7 (17.7) [n¼ 7290] 143.8 (17.4) [n¼ 4889] 139.8 (17.5) [n¼ 2146] 145.1 (21.6) [n¼ 255]
Medication prescribed in 2010:
Renin angiotensin blockers 55.9% 56.4% 53.7% 67.4%
B-blockers 46.3% 46.5% 45.4% 52.0%
Diuretics 41.4% 40.8% 41.8% 49.3%
Calcium antagonist 21.6% 21.4% 20.6% 32.9%
Statins 47.0% 48.8% 42.6% 52.3%
Vitamin D 3.7% 2.2% 6.1% 9.5%
Erythropoietin 0.3% 0.1% 0.5% 1.3%
Blood glucose lowering drugs 25.0% 27.3% 18.5% 40.1%
Antithrombotics 46.6% 48.3% 42.1% 57.6%
NSAIDs 21.3% 21.1% 22.3% 17.8%
‘‘Primary care group’’: treatment in primary care. ‘‘Consultation group’’: consultation of a nephrologist without referral. ‘‘Referral group’’: referral to secondary
care.
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available for the elderly: 71% of the population over 65
years had a renal function assessment. Diabetes was
recorded in 10 623 patients (6.5% of the population),
hypertension in 23 647 (14.5%), and cardiovascular
disease in 12 938 (8.0%).
Study population
A total of 9288 patients met the criteria for CKD,
resulting in a known adult prevalence of CKD in our
study of 5.7%. K\DOQI stages 1–2 accounted for 1.06%
(n¼ 1719) and stages 3–5 for 4.66% (n¼ 7569). Of these,
494 patients received secondary renal care and were
excluded from analysis. In the cohort of 8794 patients
treated by their GP, the guideline recommended treat-
ment in primary care in 64.9%, consultation with a
nephrologist in 31.6%, and referral in 3.5% of patients.
Table 3 provides detailed characteristics.
Process and outcome indicators
GPs completely followed the guideline in 42% (95% CI
41–43%) of their CKD patients for monitoring dis-
ease progression and in 2.4% (95% CI 1.9–2.9%) for
monitoring metabolic parameters. Blood pressure was
below 140/90mmHg in 43.1% (95% CI 41.8–44.3%) and
below 130/80mmHg in 16.4% (95% CI 15.5–17.3%) of
patients in whom a blood pressure measurement was
available (n¼ 6325). All patients considered, the achieve-
ment of blood pressure targets amounted to 31.0% and
11.8% respectively. GPs recognized decreased eGFR in
31.4% (95% CI 30–32%) by using ICPC code U99.1 for
impaired renal function. Table 2 provides further details
on quality indicators.
Associated patient and practice characteristics
A history of diabetes (OR 10.97; 95% CI 9.75–12.34) or
hypertension (OR 2.45; 95% CI 2.19–2.73), and male
gender were associated with better monitoring of
disease progression (Table 4a). A history of cardiovascu-
lar disease was negatively correlated with monitoring of
disease progression. Cardiovascular disease and highest
age were positively associated with monitoring of
metabolic parameters (Table 4b). Factors associated
with recognition of CKD were a history of cardiovascular
disease, hypertension, female sex, and highest age.
Blood pressure outcome target5140/90mmHg was
positively associated with a history of cardiovascular
disease, and had a negative correlation with highest age.
Discussion
Summary
Our results show room for improvement in all aspects of
CKD management, yet most clinical relevance lies in the
achievement of blood pressure targets (43%5140/
90mmHg). A history of diabetes was strongly associated
with high QoC.
Prevalence and recognition
In the Netherlands, the estimated community preva-
lence of CKD is 10.4%, with 5.1% in CKD stages 1–2, and
5.3% in stages 3–5.[11] For our data, this implies that
respectively 21% and 88% of expected CKD patients
could have been ascertained in primary care with the
available laboratory results. However, recognized
decreased eGFR was lower at only 31.4% of potentially
identifiable patients. Recognition is important, as it is
associated with better quality of care.[12]
Strengths and limitations
A key strength of our study is the utilization of routine
general practice data, which provides a realistic view on
quality of care. Our study represents a large proportion
Table 4a. Significant results of multilevel logistic regression model on the association between patient and practicecharacteristics and
QoC.
Variable Monitoring disease progression
eGFR Albumin urine Fasting glucose Blood pressure Complete
Patient characteristics:
Age (18–45 years as reference)
45–60 years 1.46 (1.04–2.05) 0.99 (0.71–1.40) 1.61 (1.16–2.25) 1.82 (1.29–2.58) 1.15 (0.79–1.68)
60–75 years 1.99 (1.43–2.76) 1.03 (0.74–1.24) 2.09 (1.52–2.87) 2.59 (1.85–3.61) 1.43 (0.99–2.05)
475 years 2.47 (1.77–3.43) 0.81 (0.58–1.12) 1.58 (1.15–2.18) 2.90 (2.08–4.04) 1.20 (0.83–1.72)
Male sex 1.28 (1.16–1.42) 1.26 (1.13–1.40)
Diabetes 2.98 (2.58–3.45) 9.33 (8.34–10.44) 7.07 (6.22–8.04) 4.14 (3.62–4.74) 10.97 (9.75–12.34)
Hypertension 1.84 (1.64–2.07) 2.15 (1.94–2.38) 2.42 (2.19–2.68) 4.00 (3.58–4.48) 2.45 (2.19–2.73)
Cardiovascular disease 0.87 (0.76–0.98) 0.77 (0.69–0.86) 0.82 (0.73–0.91) 0.76 (0.68–0.86)
Practice characteristics:
Urban location 0.57 (0.37–0.88) 0.52 (0.29–0.93)
Results are shown as odds ratios with 95% confidence intervals in parentheses. Outcomes on practice type and vocational training practice were not significant.
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of the (potential) CKD population in primary care, as data
on renal function were available for most patients over
65 years. To accurately report on QoC in routine general
practice, we focused on patients under care of their GP.
Several limitations should be considered. We applied
the guideline classification based on single creatinine and
albuminuria assessments whereas at least two or three
measurements are advised. This might have led to less
accurate classification, but is in line with other CKD
studies. The practices’ intrinsic motivation to participate in
the CONTACT trial might have led to a selection bias with
possible overestimation of QoC. Conversely QoC might be
underestimated due to analysis of data routinely recorded
in the EMR. It is not unlikely that blood pressure was
measured but not registered. Furthermore, GPs had little
time to implement the guideline within our studied
timeframe (1 December 2009 to 1 March 2011) consider-
ing its introduction in November 2009.
Comparison with existing literature
Our results on monitoring of disease progression are in
line with previous studies. Research on CKD stages 3–4
conducted within multi-specialty group practices, hous-
ing both GPs and nephrologists, found a comparable
eGFR assessment rate (86%), and a slightly lower
albuminuria testing rate (30%).[6] Also, impressive
results are shown in the United Kingdom, where they
recorded an 82% albuminuria testing rate in CKD stages
3–5.[13] Of possible influence is the pay for performance
system: the Quality and Outcomes Framework (QOF). In
the Netherlands, GPs are not given incentives to manage
CKD, but for diabetes management local financial
incentives exist.[14]
Outcomes on metabolic parameter monitoring were
relatively low in our study. The earlier mentioned multi-
specialty group study reported two- to threefold more
monitoring of haemoglobin, calcium, and PTH.[6]
Nephrologists’ presence close to GPs may account for
these differences.
The overall level of CKD recognition is not exceptional
in our study, as other studies report electronic docu-
mentation of CKD of between 4% and 38%.[6,7,12,15]
Low recognition may well be related to hurdles that
doctors experience in assigning a CKD diagnosis.[16]
Blood pressure targets were equally met in most other
studies: an Italian study reported blood pressures5140/
90mmHg in 45% of CKD patients; other reports mention
blood pressures5130/80mmHg in 13% to 54% of patients
depending on the included CKD stages.[12,17,18] The QOF
shows strong results with blood pressures5140/85mmHg
in 74% of the CKD population.[13]
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Research shows that patient factors associated with
high QoC are concurrent diabetes, hypertension, or
coronary artery disease, age475 years, and male
sex.[6,18–20] Our findings are comparable, except that
cardiovascular disease was negatively associated with
monitoring of disease progression. Possibly, monitoring
was left to the discretion of a cardiologist.
Results derived from the QOF show that vocational
training practices, group practices, and practices in less
socially deprived areas were associated with a higher
QoC in general.[21,22]
Implications for research and/or practice
In CKD stages 1 and 2 we found a high QoC for
monitoring of disease progression. We hypothesize that
the high prevalence of diabetes in these patients (62%),
and their treatment supported by an evidence-based
primary care-generated diabetes guideline, is key to their
renal function and albuminuria assessments.[23,24] This
guideline has been developed in, by, and for general
practice, with the objective to translate disease-specific
recommendations into a framework of person-centred
care over time. Since its introduction in 1989, the
guideline has been revised and updated in relation to
scientific progress but also following practice-based
experiences in its implementation.[25] Our findings
suggest that embedding of CKD care in a support
model and organization comparable to diabetes would
stand the best chance to improve QoC in general
practice.[26] This should not be a new single disease
model, but should support GP-based CKD care and
preferably be integrated in existing support models for
chronic care to prevent fragmentation.[27]
Feedback on laboratory results and GP education to
increase CKD recognition can assist GPs to better identify
CKD patients.[12] Periodic reviewing of EMRs, with or
without the support of nephrologists, could be a
component of support models.[28] Introduction of a
pay-for-performance system for CKD management has
shown favourable results in the UK.[17] Quality improve-
ment strategies should focus on better recognition,
systematic monitoring of disease progression including
albuminuria, and blood pressure targets.
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